Peroxisomal β-Oxidation Enzyme, DECR2, Regulates Lipid Metabolism and Promotes Treatment Resistance in Advanced Prostate Cancer

The impact of 2,4-dienoyl CoA reductase 2 (DECR2) and peroxisomal β-oxidation inhibition via thioridazine was examined in vitro, in vivo, and in clinical prostate tumours cultured ex vivo.